Navigation Links
Study in Science holds promise for a new approach to drug therapy

Researchers believe they have found a way to change the action of 60 percent of currently available medications, in some cases making them many times more effective, according to an article published in the April 21 edition of the journal Science. The discovery has the potential to improve treatments for diseases including heart disease, cancer, diabetes, depression and arthritis. The study describes a new way to manipulate perhaps the most important signaling mechanism in human cells: G-protein coupled receptors (GPCRs).

Human cells must be able to send signals that switch life processes on and off as they react to the nutrients, toxins, hormones and even the light particles they are exposed to. GPCRs are a key part of such signaling cascades, passing on messages that make vision possible, carry nerve messages, enable white blood cells to attack infection and set the timing of the heartbeat. Faulty GPCR signaling, on the other hand, plays a key role in several major diseases. As a result, GCPRs are targeted by 12 of the top 20 selling drugs, including Coreg for congestive heart failure, Cozaar for high blood pressure, Zoladex for breast cancer, Buspar for anxiety and Clozaril for schizophrenia, as well as by Zantac and Claritin. Together the drug class accounts for $200 billion in annual sales.

Authors of the current study believe they have found a new way to regulate the same GCPR pathways, but at different points. Where most drugs change the behavior of GPCRs on the outside of cells, the new class of drugs seeks to influence related signaling on the inside. Early studies suggest that the newly discovered "drug candidates" can provide better control of pathways involved in pain relief, inflammation and heart disease, while leaving healthy functions in place.

"We believe we have discovered a new class of drugs that could make current drugs more effective, but that also represents a completely new, independent way of treating the same disease
'"/>

Source:University of Rochester Medical Center


Page: 1 2 3 4 5

Related biology news :

1. Novel Asthma Study Shows Multiple Genetic Input Required; Single-gene Solution Shot Down
2. Emory Study Tests Bone Marrow Stem Cells to Improve Circulation in Legs
3. UCLA Study Shows One-Third of Drug Ads in Medical Journals Do Not Contain References Supporting Medical Claims
4. Study Demonstrates Gene Expression Microarrays are Comparable and Reproducible
5. Study Links Ebola Outbreaks To Animal Carcasses
6. Breakthrough Microarray-based Technology for the Study of Cancer
7. NYU Study Reveals How Brains Immune System Fights Viral Encephalitis
8. Study finds more than one-third of human genome regulated by RNA
9. Leukemia Drug Breakthrough Study In New England Journal Of Medicine
10. Study identifies predictors of HIV drug resistance in patients beginning triple therapy
11. New Study from Affymetrix Laboratories Points to Changing View of How Genome Works
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Study Science holds promise for new approach drug therapy

(Date:5/27/2015)... , May 27, 2015   Codonics ... safety systems and image documentation solutions and ... comprehensive, technologically-advanced automation solutions, is pleased to ... The Codonics® Safe Label System® (SLS), an ... conjunction with the Omnicell Anesthesia Workstation, helps ...
(Date:5/26/2015)... , May 26, 2015 ... announced the addition of the "Saudi Arabia ... report to their offering. ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... Arabia is projected to grow at ... high growth is attributed to the surging demand ...
(Date:5/25/2015)... May 25, 2015  Australia,s market for wearable technologies ... 2014 saw the advent of several trials and prototypes. ... 2015 is expected to ignite interest in wearables as ... Australia . This in turn will spur ... drive new partnerships amongst vendors and distributors. ...
Breaking Biology News(10 mins):Codonics and Omnicell Expand Partnership 2Codonics and Omnicell Expand Partnership 3Codonics and Omnicell Expand Partnership 4Saudi Arabia Biometric Systems Market Forecast and Opportunities, 2020 with Morpho Safran, ZK Technlogy, and Suprema Dominating 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4
... has published a paper today that is the most ... temperatures are having on the worlds coral reefs. ... Change and Ocean Acidification, co-authored by seventeen marine scientists ... will not survive the drastic increases in global temperatures ...
... Mass. -- A pioneering study of wild chimpanzees has ... experience menopause, rebutting previous studies of captive individuals which ... 35 to 40 years of age. Together with ... -- described this week in the journal Current Biology ...
... the Open Access publisher for Physics, Mathematics and ... CERN and DESY high-energy physics laboratories. Under ... charges for all research published by their investigators ... A. PMC Physics A is edited by ...
Cached Biology News:Immediate action needed to save corals from climate change 2Immediate action needed to save corals from climate change 3Wild chimpanzees appear not to regularly experience menopause 2Top physics laboratories sign up to open access with PhysMath Central 2
(Date:5/27/2015)... Mass. , May 27, 2015  RXi ... company focused on discovering and developing innovative therapies ... today provided an update on the status of the ... Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ... were 3,085 and 21 shares of Series A ...
(Date:5/26/2015)... Regenestem Network has announced ... in Buenos Aires, Argentina. The clinic will be lead ... Pastrana has assembled a multidisciplinary team of medical professionals ... state-of-the-art Puerto Madero office. , The new Regenestem ... IV clinical studies in cellular therapies, and establish Regenestem ...
(Date:5/26/2015)... and HILDEN, Germany ... QIAGEN N.V. (NASDAQ: QGEN ; Frankfurt Prime ... its QIAGEN Clinical Insight ® (QCI™) bioinformatics ... to interpret and report on genomic variants identified ... applications for the bioinformatics platform are in oncology, ...
(Date:5/26/2015)... -- Tianyin Pharmaceutical Inc. (NYSE Amex: TPI ), ... modernized traditional Chinese medicine (mTCM), branded generics and active ... of Shareholders for fiscal year ended June 30, 2014 ... office located in Chengdu, China ... in Chengdu, China ) on May ...
Breaking Biology Technology:RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 2RXi Pharmaceuticals Provides an Update on Series A and Series A-1 Preferred Stock 3Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 2Regenestem Network and Silvina Pastrana, M.D. Announce the Opening of a New Stem Cell Clinic in Buenos Aires 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 2QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 3QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 4QIAGEN Launches Clinical Bioinformatics Platform for Next-Generation Sequencing 5TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 2TPI Adjourned Its 2014 Annual Shareholder Meeting and Received Notice of Non-Compliance with NYSE MKT Continued Listing Requirements 3
... , NAGOYA, Japan , Jan. ... with the collaboration of Osaka University, has successfully ... and H3N2) type influenza virus by utilizing blood samples from ... Kazuyoshi Ikuta , Ph. D., at the Department of Virology, ...
... , TUALATIN, Ore. , ... Board: WYNX), a platform company dedicated to the acquisition, ... that it has reached an agreement with British-based Ingenion ... generation Gas Quality Inferential Measurement Device (GasPT2). , The ...
... LEIDEN, The Netherlands , January ... collaborations that are extremely,valuable for pharmaceutical research in the ... of the Top Institute, which was published today. In,the report, ... that,TI Pharma is well on its way to achieving the ...
Cached Biology Technology:Generation of Fully Human Monoclonal Antibodies Neutralizing Influenza Virus - Use of SPYMEG as a novel human lymphocyte fusion partner 2Generation of Fully Human Monoclonal Antibodies Neutralizing Influenza Virus - Use of SPYMEG as a novel human lymphocyte fusion partner 3Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 2Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 3Waytronx Announces Agreement for Development and Production of Its GASPT2 Device With UK-Based Ingenion Design Limited 4Veerman Committee Argues for Continuation of TI Pharma 2
... calibrating single-channel and multi-channel pipettes. ,Thanks to ... case, the MCP1-S is ideal for calibrating ... at the users premises. The unit is ... channels are tested automatically. Multi-channel pipettes can ...
... Yeast Whole Genome ChIP-on-chip Microarray is ... yeast (S. cerevisiae) DNA binding proteins ... Agilent DNA microarrays. This set delivers ... with greater true binding events and ...
... Yeast Whole Genome ChIP-on-chip Microarray is ... yeast (S. cerevisiae) DNA binding proteins ... Agilent DNA microarrays. This set delivers ... with greater true binding events and ...
... This kit is designed for easy ... The protocol allows for successful transformation simply ... kit reagents with cultured yeast cells. No ... washing, are required. The kit is particularly ...
Biology Products: